Why Zimmer Biomet’s TMINI deal matters now
Zimmer Biomet Holdings (ZBH) just renewed and extended its limited exclusive deal with THINK Surgical for the wireless TMINI Miniature Robotic System, keeping it tied closely to the firm’s Persona Knee platform.
For Zimmer Biomet Holdings, the renewed TMINI agreement lands at a time when the share price has inched up 2.3% year to date to US$92.08, yet the 1 year total shareholder return is down 5.4% and the 5 year total shareholder return has fallen 33.4%. This points to short term momentum picking up while longer term holders have still seen material value erosion.
Scan how Zimmer Biomet’s robotics push compares with other orthopedic and medtech players gearing up around surgery tech using our hand picked 33 healthcare AI stocks
Zimmer Biomet now trades about 16% below the average analyst target and at a much larger stated discount to intrinsic value. Is that a mispricing, or a fair warning label after years of weak long term returns?
Most Popular Narrative: 14% Undervalued
Zimmer Biomet Holdings is pinned at a fair value of $107.57 in the most followed narrative, compared with the current $92.08 share price. This puts execution on margins and cash generation under the microscope for anyone reading the TMINI news across a longer horizon.
The main factor that has to go right is successful execution of the commercial and cost-efficiency programs, including Project Optima, the global capability center in India, the Costa Rica plant, and integration of acquisitions such as Paragon 28 and iovera, while managing pressure on gross and operating margins.
The shift of R&D activities to a global capability center in India together with the build out of a manufacturing plant in Costa Rica signals a multi year cost structure reset that could ease manufacturing and engineering expenses. This would be supportive of gross margin and operating margin once initial investments and restructuring charges pass.
See why 36 investors see Zimmer Biomet Holdings as 14% undervalued.
Result: Fair Value of $107.57 (UNDERVALUED)
Still, the thesis around Zimmer Biomet can unravel if pricing pressure continues to squeeze margins, or if manufacturing restructuring drags longer on profits and cash generation.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
Mixed messages in the Zimmer Biomet story so far? Take a close look at the full set of data, then decide where you stand on the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Zimmer Biomet?
Do not stop at Zimmer Biomet. Broaden your watchlist with a few focused stock ideas curated by the Simply Wall Street Screener and keep fresh opportunities on your radar.
- Target resilient income by scanning companies that match your yield and stability preferences with 8 dividend fortresses.
- Hunt for potential mispricings using our curated list of businesses combining quality fundamentals with a margin of safety through 32 high quality undervalued stocks.
- Prioritise capital preservation by filtering for businesses with stronger balance sheets and fundamentals using list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com